Literature DB >> 210351

Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia.

A Chait, W R Hazzard, J J Albers, R P Kushwaha, J D Brunzell.   

Abstract

The removal rate of apoprotein-B (apo B) in very low density lipoprotein (VLDL) was decreased in individuals with broad beta disease when compared with endogenous hypertriglyceridemia. Following the injection of 125I-VLDL isolated from individuals with endogenous hypertriglyceridemia, both VLDL apo B fractional catabolic rate (0.058 +/- 0.029 hr-1) and VLDL apo-B turnover rate (0.300 +/- 0.070 mg/kg/hr) were lower in broad beta disease than in endogenous hypertriglyceridemia (fractional catabolic rate 0.112 +/- 0.046, p less than .05; turnover rate 0.640 +/- 0.199, p less than .005) despite equivalent plasma concentrations of VLDL-apo-B. Furthermore, conversion of VLDL apo-B to LDL was impaired in broad beta disease relative to endogenous hypertriglyceridemia. Differences in the kinetics of lipoprotein lipase-related triglyceride removal during a maximal heparin infusion were also demonstrated between these two disorders. These differences suggest an abnormality in the interaction of lipoprotein lipase with the lipoproteins of unusual composition in broad beta disease. This is further supported by the normalization of lipoprotein composition in broad beta disease by estrogen therapy, with a simultaneous change in the kinetics of lipoprotein lipase-related triglyceride removal towards those seen in endogenous hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210351     DOI: 10.1016/0026-0495(78)90151-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

Review 1.  Apolipoprotein E.

Authors:  V I Zannis; J L Breslow
Journal:  Mol Cell Biochem       Date:  1982-01-16       Impact factor: 3.396

2.  Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL.

Authors:  Andreas K Kateifides; Irina N Gorshkova; Adelina Duka; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2011-04-19       Impact factor: 5.922

3.  LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes.

Authors:  Susan J Murdoch; Andrew P Boright; Andrew D Paterson; Bernard Zinman; Michael Steffes; Patricia Cleary; Karen Edwards; Santica S Marcovina; Jonathan Q Purnell; John D Brunzell
Journal:  Atherosclerosis       Date:  2006-06-05       Impact factor: 5.162

4.  Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia.

Authors:  S M Grundy; H Y Mok; L Zech; D Steinberg; M Berman
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

5.  Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.

Authors:  A F Stalenhoef; M J Malloy; J P Kane; R J Havel
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

6.  Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

7.  Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.

Authors:  R W Milne; P K Weech; L Blanchette; J Davignon; P Alaupovic; Y L Marcel
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

Review 8.  Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.

Authors:  Alan Chait; Henry N Ginsberg; Tomas Vaisar; Jay W Heinecke; Ira J Goldberg; Karin E Bornfeldt
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

9.  Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.

Authors:  C Ehnholm; R W Mahley; D A Chappell; K H Weisgraber; E Ludwig; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

Review 10.  APOE2: protective mechanism and therapeutic implications for Alzheimer's disease.

Authors:  Zonghua Li; Francis Shue; Na Zhao; Mitsuru Shinohara; Guojun Bu
Journal:  Mol Neurodegener       Date:  2020-11-04       Impact factor: 18.879

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.